Abstract: Methods are disclosed for regulating ovulation or fertility in female mammals, for regulating spermatogenesis in males and for treating conditions such as endometriosis. Administration of effective amounts of an FSH-Inhibiting Protein (FSH-IP) can be used for female contraception and also for male contraception by preventing sperm production. FSH-IP, in its native form, is a glycosylated protein having an apparent molecular weight of about 50,000 Daltons (50kD) which inhibits the production of estradiol that would otherwise be stimulated by FSH in certain cells, such as granulosa cells. Antibodies to these FSH-IP proteins, preferably of monoclonal form can be produced using techniques presently known in the art and are useful for treatment to promote ovulation or superovulation in mammals, including humans and livestock.
Type:
Grant
Filed:
March 20, 1989
Date of Patent:
August 6, 1991
Assignee:
The Salk Institute for Biological Studies
Abstract: Bifunctional chemicals useful for linking aldehyde containing moieties to moieties containing functionalities which are or can be reactive with sulfhydryl are claimed and have the formula:L--S--(CH.sub.2).sub.n1 --CONH--SPACER--NH--XwhereinL is a leaving group selected from --H or --S--Ar, wherein Ar represents optionally substituted phenyl or pyridyl;n.sub.1 =2-4;X is selected from: --CO--Y--CONHNH.sub.2, a hydrazide; ##STR1## a hydrazine; ##STR2## a hydrazine; --CO--Y--NH--CONHNH.sub.2, a semicarbazide; and --CO--Z--NH--CSNHNH.sub.2, a thiosemicarbazide;wherein Y is alkylene or oxaalkylene and Z is alkylene or a polypeptide residue briding the N-terminal amino group and C-terminal carboxy group thereof;the SPACER is oxaalkylene or oxaalkylene substituted with hydroxyl and specifically includes residues having formulas selected froma) --(CH.sub.2).sub.n2 --O--(CH.sub.2).sub.n2 --O--(CH.sub.2).sub.n2 -- wherein each n2 is independently 2-4 andb) ##STR3## wherein n3 is 2-6.
Abstract: The present invention provides a hapten-protein conjugate, wherein a hapten is bound to the reducing end of a sugar which consists of up to 10 monosaccharide units and on a free CH.sub.2 OH group on the other end of the sugar, which is in the .alpha.-position to a hydroxyl group, is bound a protein.
Type:
Grant
Filed:
January 25, 1989
Date of Patent:
July 16, 1991
Assignee:
Boehringer Mannheim GmbH
Inventors:
Erasmus Huber, Hans-Georg Batz, Herbert von der Eltz, Christian Klein
Abstract: Cytotoxic antibody conjugates in which a folic acid-antagonistic folic acid analogue is bound to an antibody or its fragment through an oligopeptide. The conjugates can be used as a chemotherapeutic agent against malignant tumors.
Abstract: Small cell lung carcinoma cells (SCLC) contain gastrin releasing peptide (GRP) receptors. The response of the cells to GRP is rapid growth. We have found a group of peptide derivatives that act as GRP antagonists by blocking the binding of GRP to its receptor thereby inhibiting the growth of cells that are sensitive to the growth promoting activity of GRP.
Abstract: Conjugates of antibodies and cytotoxic methotrexate drugs make use of linkers between the drug and antibody which are simple organic groups, wherein the link to the antibody is an acyl group and the link to the drug is an alkylidene hydrazide.
Type:
Grant
Filed:
August 8, 1988
Date of Patent:
July 2, 1991
Assignee:
Eli Lilly and Company
Inventors:
David A. Johnson, Bennett C. Laguzza, William L. Scott
Abstract: A N-(4-aminobutyl)amphetamine-protein complex has been synthesized to be used as an immunogen to prepare an antibody having a high affinity to methamphetamine. The antibody prepared by the use of the complex has 1,000 times the affinity to methamphetamine as that of an antibody prepared by the use of N-(4-aminobutyl)methamphetamine-protein complex as an immunogen.
Type:
Grant
Filed:
August 31, 1989
Date of Patent:
June 25, 1991
Assignee:
Matsushita Electric Industrial Co., Ltd.
Abstract: Heterobifunctional crosslinkers up to about 34 .ANG. in length consisting of a sulfhydryl reactive group linked to a spacer group, which in turn is linked to an activated carboxylate group, that are useful for making efficacious anticancer immunotoxin conjugates as shown preferably by reacting an antibody associated amino group with the activated carboxylate group to form an antibody crosslinker complex and reacting the antibody crosslinker complex with a cytotoxin having a reactive sulfhydryl group with the sulfhydryl reactive group of the crosslinker, and using the conjugates so produced to treat cancer patients.
Type:
Grant
Filed:
October 15, 1990
Date of Patent:
June 18, 1991
Assignee:
Cetus Corporation
Inventors:
L. L. Houston, Lois Aldwin, Danute E. Nitecki
Abstract: The subject of the present invention is conjugates of vinca (indole-dihydroindole) derivatives carrying a detergent chain of at least 7 aliphatic carbon atoms in the C-3 position bonded via a covalent bond to a macromolecular carrier of polypeptide character, and also pharmaceutical compositions containing these conjugates and a process of preparation.
Abstract: Small cell lung carcinoma cells (SCLC) contain gastrin releasing peptide (GRP) receptors. The response of the cells to GRP is rapid growth. We have found a group of peptide derivatives that act as GRP antagonists by blocking the binding of GRP to its receptor thereby inhibiting the growth of cells that are sensitive to the growth promoting activity of GRP.
Type:
Grant
Filed:
May 24, 1988
Date of Patent:
May 28, 1991
Assignee:
Merck & Co., Inc.
Inventors:
Mark W. Riemen, Allen I. Oliff, Walfred S. Saari, David C. Heimbrook
Abstract: A drug-protein conjugate of the general formula (I): ##STR1## where the moiety A--NH-- is the condensation product of an anticancer antibiotic having a free amino group, n is 0, 1 or 2, m is 0, 1, 2 or 3, the moiety --NHAB is the condensation product of a protein having a free amino group and the moiety ##STR2## is the condensation product of an amino acid of the formula HOOC--AA--NH.sub.2.
Abstract: Diphosphonate-derivatized macromolecules, such as proteins, suitable for use as technetium-99m-based scanning agents and as anticalcification agents are disclosed. The scanning agents are prepared by combining Tc-99m in a +3, +4 and/or +5 oxidation state with the diphosphonate-derivatized macromoleules. Also disclosed are pharmaceutical compositions containing these diphosphonate-derivatized macromolecules and methods for scintigraphic imaging using these diphosphonate-derivatized macromolecules labeled with Tc-99m.
Type:
Grant
Filed:
May 11, 1989
Date of Patent:
April 30, 1991
Assignee:
The Procter & Gamble Company
Inventors:
James J. Benedict, Charles R. Degenhardt, James W. Poser
Abstract: Modified antibodies or antigen-recognizing fragments are prepared with a linker consisting of a malonate, wherein the antibody or fragment thereof is attached through a carbonyl to an ester or amide group on one of the malonate carboxyls, and the drug is linked through a methylene to the 2-position carbon of the malonate.
Abstract: Novel methods for covalent attachment of antibodies, antigens, or other molecules to solid phases using extended length heterobifunctional crosslinking reagents are disclosed. The resulting derivatized solid phases can be used in diagnostic assays.
Type:
Grant
Filed:
October 11, 1988
Date of Patent:
March 26, 1991
Assignee:
Abbott Laboratories
Inventors:
Christopher Bieniarz, Christopher J. Welch, Grady Barnes, Carol A. Schlesinger
Abstract: Novel polyamino acid based coupling agents are disclosed. These reagents are useful for conjugating proteins (e.g. antibodies to enzymes) for use in diagnostic assays.
Type:
Grant
Filed:
September 22, 1988
Date of Patent:
February 19, 1991
Assignee:
Abbott Laboratories
Inventors:
Christopher Bieniarz, Christopher J. Welch, Grady Barnes